VaultRNA Therapy™ proposes a non-invasive, post-genomic therapeutic strategy using engineered vault ribonucleoprotein particles to deliver corrective synthetic mRNA to cells affected by genetic mutations. Unlike gene editing, this approach does not alter the genome but restores functional protein synthesis. The framework addresses the central challenge of mRNA stability through vault particle encapsulation, pH-responsive release, and chemical mRNA modification compatibility. Duchenne Muscular Dystrophy (DMD) is presented as the primary model case. This is an original independent research contribution by Bernadett Lovey, first published February 2026.
Bernadett Lovey (Sun,) studied this question.